Pediatric population with cystic fibrosis in the centre of Portugal: candidates for new therapies

Abstract Objectives: Cystic fibrosis (CF) is a severe autosomal recessive disease that results from mutations in a gene encoding the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a chloride channel. This study aims to characterize the clinical and genetic features of a cohort of pediatric people with CF (PwCF) in the center of Portugal and to determine which ones are candidates for the new drugs modulating the CFTR channel. Methods: A review of the demographic, genetic and clinical characteristics of PwCF undergoing follow-up at a CF reference center was carried out. Results: Twenty-three PwCF (12 male), with a median age of 12 years, were followed up. All patients carry the F508del mutation in at least one allele. Fifteen PwCF were F508del-homozygous, median BMI z-score was -0.13, all are pancreatic insufficient and median FEV1 value was 78.1%. These PwCF are eligible for dual therapy (lumacaftor/tezacaftor+ivacaftor) and for triple therapy (tezacaftor+ivacaftor+elexacaftor). PwCF with 711 +1G->T (n = 2), 2184insA (n = 1) mutations and a novel mutation c.3321dup (n = 1) have minimal function mutation and patients with a residual function mutation: R334W (n = 3) and P5L (n = 1) have a less severe phenotype. All these patients, because they also carry F508del mutation, are elegible to triple therapy. Conclusions: Genetic and molecular characterization of PwCF poses an important step not just for CF diagnosis and prognosis which is tightly correlated with the clinical phenotype, but also for the eligibility of CFTR modulator drugs.

Saved in:
Bibliographic Details
Main Authors: Roda,Juliana, Teixeira,Teresa, Silva,Iris Al, Silva,Teresa Reis, Ferreira,Ricardo, Amaral,Margarida D., Oliveira,Guiomar
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Pediatria 2022
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572022000200212
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0021-75572022000200212
record_format ojs
spelling oai:scielo:S0021-755720220002002122022-04-18Pediatric population with cystic fibrosis in the centre of Portugal: candidates for new therapiesRoda,JulianaTeixeira,TeresaSilva,Iris AlSilva,Teresa ReisFerreira,RicardoAmaral,Margarida D.Oliveira,Guiomar Mutations Clinical manifestations Ivacaftor Tezacaftor Lumacaftor Elexacaftor Abstract Objectives: Cystic fibrosis (CF) is a severe autosomal recessive disease that results from mutations in a gene encoding the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a chloride channel. This study aims to characterize the clinical and genetic features of a cohort of pediatric people with CF (PwCF) in the center of Portugal and to determine which ones are candidates for the new drugs modulating the CFTR channel. Methods: A review of the demographic, genetic and clinical characteristics of PwCF undergoing follow-up at a CF reference center was carried out. Results: Twenty-three PwCF (12 male), with a median age of 12 years, were followed up. All patients carry the F508del mutation in at least one allele. Fifteen PwCF were F508del-homozygous, median BMI z-score was -0.13, all are pancreatic insufficient and median FEV1 value was 78.1%. These PwCF are eligible for dual therapy (lumacaftor/tezacaftor+ivacaftor) and for triple therapy (tezacaftor+ivacaftor+elexacaftor). PwCF with 711 +1G->T (n = 2), 2184insA (n = 1) mutations and a novel mutation c.3321dup (n = 1) have minimal function mutation and patients with a residual function mutation: R334W (n = 3) and P5L (n = 1) have a less severe phenotype. All these patients, because they also carry F508del mutation, are elegible to triple therapy. Conclusions: Genetic and molecular characterization of PwCF poses an important step not just for CF diagnosis and prognosis which is tightly correlated with the clinical phenotype, but also for the eligibility of CFTR modulator drugs.info:eu-repo/semantics/openAccessSociedade Brasileira de PediatriaJornal de Pediatria v.98 n.2 20222022-04-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572022000200212en10.1016/j.jped.2021.05.010
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Roda,Juliana
Teixeira,Teresa
Silva,Iris Al
Silva,Teresa Reis
Ferreira,Ricardo
Amaral,Margarida D.
Oliveira,Guiomar
spellingShingle Roda,Juliana
Teixeira,Teresa
Silva,Iris Al
Silva,Teresa Reis
Ferreira,Ricardo
Amaral,Margarida D.
Oliveira,Guiomar
Pediatric population with cystic fibrosis in the centre of Portugal: candidates for new therapies
author_facet Roda,Juliana
Teixeira,Teresa
Silva,Iris Al
Silva,Teresa Reis
Ferreira,Ricardo
Amaral,Margarida D.
Oliveira,Guiomar
author_sort Roda,Juliana
title Pediatric population with cystic fibrosis in the centre of Portugal: candidates for new therapies
title_short Pediatric population with cystic fibrosis in the centre of Portugal: candidates for new therapies
title_full Pediatric population with cystic fibrosis in the centre of Portugal: candidates for new therapies
title_fullStr Pediatric population with cystic fibrosis in the centre of Portugal: candidates for new therapies
title_full_unstemmed Pediatric population with cystic fibrosis in the centre of Portugal: candidates for new therapies
title_sort pediatric population with cystic fibrosis in the centre of portugal: candidates for new therapies
description Abstract Objectives: Cystic fibrosis (CF) is a severe autosomal recessive disease that results from mutations in a gene encoding the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a chloride channel. This study aims to characterize the clinical and genetic features of a cohort of pediatric people with CF (PwCF) in the center of Portugal and to determine which ones are candidates for the new drugs modulating the CFTR channel. Methods: A review of the demographic, genetic and clinical characteristics of PwCF undergoing follow-up at a CF reference center was carried out. Results: Twenty-three PwCF (12 male), with a median age of 12 years, were followed up. All patients carry the F508del mutation in at least one allele. Fifteen PwCF were F508del-homozygous, median BMI z-score was -0.13, all are pancreatic insufficient and median FEV1 value was 78.1%. These PwCF are eligible for dual therapy (lumacaftor/tezacaftor+ivacaftor) and for triple therapy (tezacaftor+ivacaftor+elexacaftor). PwCF with 711 +1G->T (n = 2), 2184insA (n = 1) mutations and a novel mutation c.3321dup (n = 1) have minimal function mutation and patients with a residual function mutation: R334W (n = 3) and P5L (n = 1) have a less severe phenotype. All these patients, because they also carry F508del mutation, are elegible to triple therapy. Conclusions: Genetic and molecular characterization of PwCF poses an important step not just for CF diagnosis and prognosis which is tightly correlated with the clinical phenotype, but also for the eligibility of CFTR modulator drugs.
publisher Sociedade Brasileira de Pediatria
publishDate 2022
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572022000200212
work_keys_str_mv AT rodajuliana pediatricpopulationwithcysticfibrosisinthecentreofportugalcandidatesfornewtherapies
AT teixeirateresa pediatricpopulationwithcysticfibrosisinthecentreofportugalcandidatesfornewtherapies
AT silvairisal pediatricpopulationwithcysticfibrosisinthecentreofportugalcandidatesfornewtherapies
AT silvateresareis pediatricpopulationwithcysticfibrosisinthecentreofportugalcandidatesfornewtherapies
AT ferreiraricardo pediatricpopulationwithcysticfibrosisinthecentreofportugalcandidatesfornewtherapies
AT amaralmargaridad pediatricpopulationwithcysticfibrosisinthecentreofportugalcandidatesfornewtherapies
AT oliveiraguiomar pediatricpopulationwithcysticfibrosisinthecentreofportugalcandidatesfornewtherapies
_version_ 1756376011710136320